Abstract:Atorvastatin calcium (AC), a cholesterol-lowering medication, has limited oral bioavailability (14 %) and adverse impacts on the gastrointestinal tract (GIT), liver, and muscle. So, in an effort to improve the poor availability and overcome the hepatotoxicity complications attendant to peroral AC administration, transdermal transfersomal gel (AC-TFG) was developed as a convenient alternative delivery technique. The impact of utilizing an edge activator (EA) and varying the phosphatidylcholine (PC): EA molar ratio on the physico-chemical characteristics of the vesicles was optimized through a Quality by Design (QbD) strategy. The optimal transdermal AC-TFG was tested in an ex-vivo permeation study employing full-thickness rat skin, Franz cell experiments, an in-vivo pharmacokinetics and pharmacodynamics (PK/PD) evaluation, and a comparison to oral AC using poloxamer-induced dyslipidemic Wister rats. The optimized AC-loaded TF nanovesicles predicted by the 23-factorial design strategy had a good correlation with the measured vesicle diameter of 71.72 ± 1.159 nm, encapsulation efficiency of 89.13 ± 0.125 %, and cumulative drug release of 88.92 ± 3.78 % over 24 h. Ex-vivo data revealed that AC-TF outperformed a free drug in terms of permeation. The pharmacokinetic parameters of optimized AC-TFG demonstrated 2.5- and 13.3-fold significant improvements in bioavailability in comparison to oral AC suspension (AC-OS) and traditional gel (AC-TG), respectively. The transdermal vesicular technique preserved the antihyperlipidemic activity of AC-OS without increasing hepatic markers. Such enhancement was proven histologically by preventing the hepatocellular harm inflicted by statins. The results showed that the transdermal vesicular system is a safe alternative way to treat dyslipidemia with AC, especially when given over a long period of time.

Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-β-cyclodextrin complex

Amorphous Solid Dispersion with Increased Gastric Solubility in Tandem with Oral Disintegrating Tablets: a Successful Approach to Improve the Bioavailability of Atorvastatin

Development and Characterization of Binary Solid Lipid Nano Suspension of Atorvastatin: In-Vitro Drug Release and In-Vivo Pharmacokinetic Studies

Investigation of the Improved Effects of 2-Hydroxypropyl-β-cyclodextrin on Solubility, Dissolution Rate, and Intestinal Absorptive Profile of Tanshinone IIA in Rats

Development of Atorvastatin Calcium Biloaded Capsules for Oral Administration of Hypercholesterolemia

Complexation of Tanshinone IIA with 2-Hydroxypropyl-β-cyclodextrin: Effect on Aqueous Solubility, Dissolution Rate, and Intestinal Absorption Behavior in Rats

Preparation and Pharmacokinetics in Rat of Osthol-Β-cd Inclusion Complex Dispersible Tablets

Characterization And In Vivo Evaluation Of An Inclusion Complex Of Oridonin And 2-Hydroxypropyl-Beta-Cyclodextrin

Atorvastatin calcium inclusion complexation with polysaccharide arabinogalactan and saponin disodium glycyrrhizate for increasing of solubility and bioavailability

Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization

Preparation of Atorvastatin Calcium-Dipicolinic Acid Multicomponent Solids by Liquid-Assisted Grinding Method to Increase Solubility

Physicochemical Characteristics and Oral Bioavailability of Andrographolide Complexed with Hydroxypropyl-Beta-cyclodextrin.

Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin.

Study on the Intestinal Absorption Profiles of Tanshinone IIA and Its Inclusion Complex with Cyclodextrin in Rats.

Preparation and evaluation of self-microemulsifying drug delivery systems containing atorvastatin

Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS)

Formulation, and optimization of transdermal Atorvastatin Calcium-Loaded Ultra-flexible vesicles; ameliorates poloxamer 407-caused dyslipidemia

Inclusion Complex of Tamibarotene with Hydroxypropyl-Β-cyclodextrin: Preparation, Characterization, In-Vitro and In-Vivo Evaluation

Preparation, Physicochemical Characterization and in Vitro Dissolution Studies of Azithromycin-Cyclodextrin Inclusion Complexes

Complexation of Z-ligustilide with Hydroxypropyl-Β-cyclodextrin to Improve Stability and Oral Bioavailability.

Studies on interaction of atorvastatin calcium with beta-cyclodextrin and its application